Involvement of N-terminally truncated variants of p73, ΔTAp73, in head and neck squamous cell cancer. A comparison with p53 mutations

Cell Cycle

Volumn 7, Issue 11, 2008, Pages 1587-1596

  Faridoni Laurens, Laetitia ^a   Tourpin, Sophie ^a   Alsafadi, Samar ^a   Barrois, Michel ^a   Temam, Stephane ^a   Janot, François ^a   Koscielny, Serge ^a   Bosq, Jacques ^a   Bénard, Jean ^a   Ahomadegbe, Jean Charles ^a,b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

Head and neck cancers; p53; p73

Indexed keywords

ISOPROTEIN; PROTEIN P53; PROTEIN P73; TAP73 PROTEIN; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; OVERALL SURVIVAL; SQUAMOUS CELL CARCINOMA; TRANSACTIVATION; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

EID: 45849097594     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.11.5894     Document Type: Article

References (36)

1. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lellas JM, Dumont X, Ferrara P, McKeon F, Caput D. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma, other human cancers. Cell 1997;90:809-19.
2. Jost CA, Marin MC, Kaelin Jr WG. P73 is a human p53-related protein that can induce apoptosis. Nature 1997; 389:191-4.
3. Trink B, Okami K, Wu L, Sriuranpong V, Jen J, Sidransky D. A new human p53 homologue. Nat Med 1998; 4:747.
4. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dötsch V, Andrews NC, Caput D, McKeon F. p63, a p53 homolog at 3q27-29, encodes multiples products with transactivating, death-inducing and dominant-negative activities. Mol Cell 1998; 2:305-16.
5. De Laurenzi V, Costanzo A, Barcaroli D, Terrinoni A, Falco M, Annichiarico-Tetruzelli M, Levrero M, Melino G. Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med 1998; 188:1763-8.
6. Bell HS, Ryan KM. Targeting the p53 family for cancer therapy: 'big brother' joins the fight. Cell cycle 2007; 6:1995-2000.
7. Bénard J, Douc Rasy S, Ahomadegbe JC. TP53 family members and human cancers. Human mutation 2003; 21:182-91.
8. Miro-Mur F, Meiller A, Haddada H, May E. p73alpha expression induces both accumulation and activation of wt-p53 independent of the p73alpha transcriptional activity. Oncogene 22:5451-6.
9. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, Vagner C, Bonnet H, Dikkes P, Sharpe A, McKeon F, Caput D. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000; 404:99-103.
10. Flores ER, Sengupta S, Miller JB, Newman JJ, Bronson R, Crowle D, Yang A, McKeon F, Jacks T. Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005; 7:363-73.
11. Ishimoto O, Kawahara C, Enjo K, Obinata M, Nukiwa T, Ikawa S. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res 2002; 62:636-41.
12. Stiewe T, Zimmermann S, Frilling A, Esche H, Pützer BM. Transactivation-deficient deltap73 acts as an oncogene. Cancer Res 2002; 62:3598-02.
13. Zaika AI, Slade N, Erster SH, Sansone C, Joseph TW, Pearl M, Chalas E, Moll U. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73 is upregulated in human tumors. J Exp Med 2002; 196:765-80.
14. Casciano I, Mazzocco K, Boni L, Pagnan G, Banelli B, Allemanni G, Ponzoni M, Tonini GP, Romani M. Expression of deltaNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ 2002; 9:246-51.
15. Uramoto H, Sugio K, Oyama T, Nakat S, Ono K, Morita M, Funa K, Yasumoto K. Expression of deltaNp73 predicts poor prognosis in Lung Cancer. Clin Cancer Res 2004; 10:6905-11.
16. Concin N, Becker K, Slade N, Erster S, Mueller Holzner E, Ulmer H, Daxenbichler G, Zeimer A, Zeillinger R, Marth C, Moll UM. Transdominant deltaTAp73 isoforms are frequently upregulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res 2004; 64:2449-60.
17. Stiewe T, Tuve S, Peter M, Tannapfel A, Elmagacli AH, Pützer BM. Quantitative TP73 transcripts analysis in hepatocellular carcinomas. Clin Cancer Res 2004; 10:626-33.
18. Cui R, He J, de Fromentel CC, Martel-Planche G, Tanière P, Hainaut P. Expression of p53, p63 and p73 isoforms in squamous cell carcinoma and adenocarcinoma of esophagus. Biochem Biophys Res Commun 2006; 336:339-45.
19. Marin M, Jost CA, Brooks LA, Irwin MS, O'Nions J, Tidy JA, James N, McGregor JM, Harwood CA, Yulug IG, Vousden KH, Allday MJ, Gusterson B, Ikawa S, Hinds PW, Crook T, Kaelin WG Jr. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000; 1:47-54.
20. Bergamaschi D, Gasco M, Hiller L, Sullivan A, Syed N, Trigiante G, Yulug I, Merlano M, Numico G, Comino A, Attard M, Reelfs O, Gusterson B, Bell AK, Heath V, Tavasoli M, Farell PJ, Smith P, Lu X, Crook T. P53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003; 4:387-402.
21. Jemal A, Murray T, Samuels A, Ghafar A, Ward E, Thun MJ. Cancer Statistics 2003. CACancer J Clin 2003; 53:5-26.
22. Franceschi S, Talamini R, Barra S, Baron AE, Negri E, Bidoli E, Serraino D, La Vecchia C. Smoking and drinking in relation to cancers of the oral cavity, pharynx, larynx and oesophagus in northern Italy. Cancer Res 1990; 50:6502-07.
23. Ahomadegbe JC, Barrois M, Fogel S, LeBihan ML, Douc-Rasy S, Duvillard P, Armand JP, Riou G. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 1995; 10:1217-27.
24. Faridoni Laurens L, Bosq J, Janot F, Vayssade M, Le Bihan ML, Kaghad M, Caput D, Bénard J, Ahomadegbe JC. P73 expression in basal layers of head and neck squamous epithelium: a role in differentiation and carcinogenesis in concert with p53 and p63? Oncogene 2001; 20:5302-12.
25. Barbieri CE, Tang LJ, Brown KA, Pietenpol JA. Loss of p63 leads to increased cell migration and upregulation of genes involved in invasion and metastasis. Cancer Res 2006; 66:7589-97.
26. Boldrup L, Coates PJ, Gu X, Nylander K. ?Np63 isoforms regulate CD44 and keratins 4, 6, 14 and 19 in squamous cell carcinoma of head and neck. J Pathol 2007; 213:384-91
27. Hibi K, Trink B, Patturajan M, Westra WH, Caballero OL, Hill DE, Ratovitski EA, Jen J, Sidranski D. AIS is a oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA 2000; 97:5462-67.
28. Thurfjell N, Coates PJ, Uusitaio T, Mahani D, Dabeisteen E, Dahlqvist A, Sjöström B, Roos G, Nylander K. Complex p63 mRNA isoform expression patterns in squamous cell carcinoma of the head and neck. Int J Oncol 2004; 25:27-35.
29. Rocco JW, Ellisen LW. p63 and p73: life and death in squamous cell carcinoma. Cel Cycle 2006; 5:936-40.
30. Tabor MP, Brakenhoff RH, Ruijter-Schippers HJ, Van Der Wal JE, Snow GB, Leemans CR, Braakhuis BJ. Multiple head and neck tumors frequently originate from a single preneoplastic lesion. Am J Pathol 2002; 161:1051-60.
31. Vayssade M, Haddada H, Faridoni-Laurens L, Tourpin S, Benard J, Ahomadegbe JC. p73 functionally replaces p53 in adriamycin-treated, p53-deficient breast cancer cells. Int J Cancer 2005; 116:860-69.
32. Soussi T, Legros Y, Lubin R, Ory K, Schlichtholz B. Multifactorial analysis of p53 alteration in human cancer: a review. Int J Cancer 1994; 57:1-9.
33. Hollstein M, Shomer B, Greenblat M, Soussi T, Hovig E, Montesano R, Harris CC. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 1996; 24:141-46
34. Gaiddon C, Lokshin M, AHN J, Zhang T, Prives C. A subset of tumor-derived mutant forms of p53 downregulate p63 and p73 through a direct interaction with the p53 core domain. Moll Cell Biol 2001; 21:1874-87
35. Lanza M, Marinari B, Papoutsaki M, Giustizieri ML, D'Alessandra Y, Chimenti S, Guerrini L, Costanzo A. Cross-talks in the p53 family: ΔNp63 is an anti-apoptotic target for ?Np73? and p53 gain of function mutants. Cell Cycle 2006; 5:1996-2004.
36. Concin N, Hofstetter G, Berger A, Gehmacher A, Reimer D, Watrowski R, Tong D, Schuster E, Hefler L, Heim K, Mueller Holzner E, Marth C, Moll UM, Zeimet AG, Zeillinger R. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clin Cancer Res 2005; 11:8372-83.